BEIJING, July 23 (Reuters) - BeOne Medicines

announced on Thursday an additional $300 million investment to a

manufacturing and R&D facility in New Jersey, bringing total

U.S. manufacturing investment to more than $1 billion, it said

in a statement.

"The expansion will increase BeOne's production capacity to

manufacture its medicines and is expected to create

approximately 120 new full-time jobs," the statement reads.

"The investment supports the continued advancement of

BeOne's deep oncology pipeline of more than 35 clinical and

commercial-stage assets", it said.